Atypical Dopamine Uptake Inhibitors that Provide Clues About Cocaine's Mechanism at the Dopamine Transporter

  • Amy Hauck NewmanEmail author
  • Jonathan L. Katz
Part of the Topics in Medicinal Chemistry book series (TMC, volume 4)


The dopamine transporter (DAT) has been a primary target for cocaine abuse/addiction medicationdiscovery. However predicted addiction liability and limited clinical evaluation has provided a formidablechallenge for development of these agents for human use. The unique and atypical pharmacological profileof the benztropine (BZT) class of dopamine uptake inhibitors, in preclinical models of cocaine effects andabuse, has encouraged further development of these agents. Moreover, in vivo studies have challenged theoriginal DAT hypothesis and demonstrated that DAT occupancy and subsequent increases in dopamine producedby BZT analogues are significantly delayed and long lasting, as compared to cocaine. These important anddistinctive elements are critical to the lack of abuse liability among BZT analogues, and improve theirpotential for development as treatments for cocaine abuse and possibly other neuropsychiatric disorders.

Addiction medication discovery Benztropine Cocaine Dopamine transporter Dopamine uptake inhibitor 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987) Science 237:1219 CrossRefGoogle Scholar
  2. 2.
    Newman AH (1998) Med Chem Res 8:1 Google Scholar
  3. 3.
    Newman AH, Kulkarni SS (2002) Med Res Rev 22:1 CrossRefGoogle Scholar
  4. 4.
    Dutta AK, Zhang S, Kolhatkar R, Reith MEA (2003) Eur J Pharmacol 479:93 CrossRefGoogle Scholar
  5. 5.
    Runyon SP, Carroll FI (2006) Curr Top Med Chem 6:1825 CrossRefGoogle Scholar
  6. 6.
    Rothman RB, Baumann MH, Prisinzano TE, Newman AH (2008) Biochem Pharmacol 75:2 CrossRefGoogle Scholar
  7. 7.
    Rocha BA, Fumagalli F, Gainetdinov RR, Jones SR, Ator R, Giros B, Miller GW, Caron MG (1998) Nat Neurosci 1:132 CrossRefGoogle Scholar
  8. 8.
    Sora I, Wichems C, Takahashi N, Li XF, Zeng Z, Revay R, Lesch KP, Murphy DL, Uhl GR (1998) Proc Natl Acad Sci USA 95:7699 CrossRefGoogle Scholar
  9. 9.
    Rothman RB, Greig N, Kim A, De Costa BR, Rice KC, Carroll FI, Pert A (1992) Pharmacol Biochem Behav 43:1135 CrossRefGoogle Scholar
  10. 10.
    Vaugeois JM, Bonnet JJ, Duterte-Boucher D, Costentin J (1993) Eur J Pharmacol 230:195 CrossRefGoogle Scholar
  11. 11.
    Colpaert FC, Niemegeers CJ, Janssen PA (1979) Biochem Behav 10:535 CrossRefGoogle Scholar
  12. 12.
    Husbands SH, Kopajtic T, Izenwasser S, Bowen WD, Vilner BJ, Katz JL, Newman AH (1999) J Med Chem 42:4446 CrossRefGoogle Scholar
  13. 13.
    Katz JL, Libby TA, Kopajtic T, Husbands SM, Newman AH (2003) Eur J Pharmacol 468:109 CrossRefGoogle Scholar
  14. 14.
    Cao J, Kulkarni SS, Husbands SM, Bowen WD, Williams W, Kopajtic T, Katz JL, George C, Newman AH (2003) J Med Chem 46:2589 CrossRefGoogle Scholar
  15. 15.
    Navarro HA, Howard JL, Pollard GT, Carroll FI (2005) Abstract 67th Annual Meeting of the College on Problems of Drug Dependence Google Scholar
  16. 16.
    Carroll FI (2003) J Med Chem 46:1775 CrossRefGoogle Scholar
  17. 17.
    Newman AH, Allen AC, Izenwasser S, Katz JL (1994) J Med Chem 37:2258 CrossRefGoogle Scholar
  18. 18.
    Newman AH, Kline RH, Allen AC, Izenwasser S, George C, Katz JL (1995) J Med Chem 38:3933 CrossRefGoogle Scholar
  19. 19.
    Kline RH, Izenwasser S, Katz JL, Newman AH (1997) J Med Chem 40:851 CrossRefGoogle Scholar
  20. 20.
    Kulkarni SS, Kopajtic TA, Katz JL, Newman AH (2006) Bioorg Med Chem 14:3625 CrossRefGoogle Scholar
  21. 21.
    Campbell VC, Kopajtic TA, Newman AH, Katz JL (2005) J Pharmacol Exp Ther 315:631 CrossRefGoogle Scholar
  22. 22.
    Agoston GE, Wu JH, Izenwasser S, George C, Katz J, Kline RH, Newman AH (1997) J Med Chem 4:4329 CrossRefGoogle Scholar
  23. 23.
    Robarge MJ, Agoston GE, Izenwasser S, Kopajtic T, George C, Katz JL, Newman AH (2000) J Med Chem 43:1085 CrossRefGoogle Scholar
  24. 24.
    Newman AH, Robarge MJ, Howard IM, Wittkopp SL, Kopajtic T, Izenwasser S, Katz JL (2001) J Med Chem 44:633 CrossRefGoogle Scholar
  25. 25.
    Kulkarni SS, Grundt P, Kopajtic T, Katz JL, Newman AH (2004) J Med Chem 47:3388 CrossRefGoogle Scholar
  26. 26.
    Agoston GE, Vaughan R, Lever JR, Izenwasser S, Terry PD, Newman AH (1997) Bioorg Med Chem Lett 7:3027 CrossRefGoogle Scholar
  27. 27.
    Vaughan RA, Agoston GE, Lever JR, Newman AH (1999) J Neurosci 19:630 Google Scholar
  28. 28.
    Grundt P, Kopajtic TA, Katz JL, Newman AH (2004) Bioorg Med Chem Lett 14:3295 Google Scholar
  29. 29.
    Simoni D, Rossi M, Bertolasi V, Roberti M, Pizzirani D, Rondanin R, Baruchello R, Invidiata PFP, Tolomeo M, Grimaudo S, Merighi S, Varani K, Gessi S, Borea PA, Marino S, Savallini S, Bianchi C, Siniscalchi A (2005) J Med Chem 48:337 CrossRefGoogle Scholar
  30. 30.
    Grundt P, Kopajtic T, Katz JL, Newman AH (2005) Bioorg Med Chem Lett 15:5419 CrossRefGoogle Scholar
  31. 31.
    Meltzer PC, Liang AY, Madras BK (1994) J Med Chem 37:2001 CrossRefGoogle Scholar
  32. 32.
    Meltzer PC, Liang AY, Madras BK (1996) J Med Chem 39:371 CrossRefGoogle Scholar
  33. 33.
    Zou MF, Agoston GE, Belov Y, Kopajtic T, Katz JL, Newman AH (2002) Bioorg Med Chem Lett 12:1249 CrossRefGoogle Scholar
  34. 34.
    Zou MF, Kopajtic T, Katz JL, Newman AH (2003) J Med Chem 46:2908 CrossRefGoogle Scholar
  35. 35.
    Zou MF, Cao J, Kopajtic T, Desai RI, Katz JL, Newman AH (2006) J Med Chem 49:6391 CrossRefGoogle Scholar
  36. 36.
    Meltzer PC, Liang AY, Blundell P, Gonzalez MD, Chen Z, George C, Madras B (1997) J Med Chem 40:2661 CrossRefGoogle Scholar
  37. 37.
    Meltzer PC, Blundell P, Yong YF, Chen Z, George C, Gonzalez MD, Madras B (2000) J Med Chem 43:2982 CrossRefGoogle Scholar
  38. 38.
    Loland CJ, Desai RI, Zou MF, Cao J, Grundt P, Gerstbrein K, Sitte HH, Newman AH, Katz JL, Gether U (2008) Mol Pharm 73:813 Google Scholar
  39. 39.
    Kelleher RT (1997) Drug Abuse: the Clinical and Basic Aspects. CV Mosby Co, St. Louis Google Scholar
  40. 40.
    Izenwasser S, Terry P, Heller B, Witkin JM, Katz JL (1994) Eur J Pharmacol 263:277 CrossRefGoogle Scholar
  41. 41.
    Katz JL, Izenwasser S, Newman AH (1997) Pharmacol Biochem Behav 57:505 CrossRefGoogle Scholar
  42. 42.
    Katz JL, Izenwasser S, Kline RH, Allen AC, Newman AH (1999) J Pharmacol Exp Ther 288:302 Google Scholar
  43. 43.
    Baker LE, Riddle EE, Saunders RB, Appel JB (1993) Behav Pharmacol 1:69 Google Scholar
  44. 44.
    Kleven MS, Anthony EW, Woolverton WL (1990) J Pharmacol Exp Ther 254:312 Google Scholar
  45. 45.
    Johanson CE, Fischman MW (1989) Pharmacol Rev 41:3 Google Scholar
  46. 46.
    Woolverton WL, Rowlett JK, Wilcox KM, Paul IA, Kline RH, Newman AH, Katz JL (2000) Psychopharmacology 147:426 CrossRefGoogle Scholar
  47. 47.
    Woolverton WL, Hecht GS, Agoston GE, Katz JL, Newman AH (2001) Psychopharmacology 154:375 CrossRefGoogle Scholar
  48. 48.
    Hodos W (1961) Science 134:943 CrossRefGoogle Scholar
  49. 49.
    Gollub L, Yanagita T (1974) Bull Psychon Soc 4:263 Google Scholar
  50. 50.
    Stretch R, Gerber GJ, Lane E (1976) Can J Physiol Pharmacol 54:632 CrossRefGoogle Scholar
  51. 51.
    Beardsley PM, Balster RL (1993) Drug Alcohol Depend 34:37 CrossRefGoogle Scholar
  52. 52.
    De Beun R, Jansen E, Geerts NE, Slangen JL, Van De Poll NE (1992) Pharmacol Biochem Behav 42:445 CrossRefGoogle Scholar
  53. 53.
    Li SM, Newman AH, Katz JL (2005) J Pharmacol Exp Ther 313:1223–1230 CrossRefGoogle Scholar
  54. 54.
    Richelson E (1981) Antidepressants: Neurochemical, Behavioral and Clinical Perspectives. Raven Press, New York Google Scholar
  55. 55.
    McKearney JW (1982) Psychopharmacology 77:156 CrossRefGoogle Scholar
  56. 56.
    Tuomisto J, Tuomisto L (1980) Med Biol 58:33 Google Scholar
  57. 57.
    Bergman J, Spealman RD (1986) J Pharmacol Exp Ther 239:104 Google Scholar
  58. 58.
    Scheckel CL, Boff E (1964) Psychopharmacologia 5:198 CrossRefGoogle Scholar
  59. 59.
    Tanda G, Ebbs A, Kopajtic T, Campbell B, Newman AH, Katz JL (2007) J Pharmacol Exp Ther 321:332 CrossRefGoogle Scholar
  60. 60.
    Tanda G, Katz JL (2007) Pharmacol Biochem Behav 87:400 CrossRefGoogle Scholar
  61. 61.
    Katz JL, Kopajtic T, Agoston GE, Newman AH (2004) J Pharmacol Exp Ther 288:302 Google Scholar
  62. 62.
    Ranaldi R, Woolverton WL (2002) Psychopharmacology (Berl) 161:442 CrossRefGoogle Scholar
  63. 63.
    Wilson MC, Schuster CR (1973) Pharmacol Biochem Behav 1:643 CrossRefGoogle Scholar
  64. 64.
    Raje S, Cao J, Newman AH, Gao H, Eddington N (2003) J Pharmacol Exp Ther 307:801 CrossRefGoogle Scholar
  65. 65.
    Othman AA, Syed SA, Newman AH, Eddington ND (2007) J Pharmacol Exp Ther 320:344 CrossRefGoogle Scholar
  66. 66.
    Church WH, Justice JB, Byrd LD (1987) Eur J Pharmacol 139:345 CrossRefGoogle Scholar
  67. 67.
    Tolliver BK, Ho LB, Newman AH, Fox LM, Katz JL, Berger SP (1999) J Pharmacol Exp Ther 103:110 Google Scholar
  68. 68.
    Tanda G, Ebbs A, Newman AH, Katz JL (2005) J Pharmacol Exp Ther 313:613 CrossRefGoogle Scholar
  69. 69.
    Desai R, Kopajtic T, Koffarnus M, Newman AH, Katz JL (2005) J Neurosci 25:1889 CrossRefGoogle Scholar
  70. 70.
    Desai R, Kopajtic T, French D, Newman AH, Katz JL (2005) J Pharmacol Exp Ther 315:397 CrossRefGoogle Scholar
  71. 71.
    Bergman J, Madras BK, Johnson SE, Spealman RD (1989) J Pharmacol Exp Ther 251:150 Google Scholar
  72. 72.
    Volkow ND, Fowler JS, Wang GJ (2002) Behav Pharmacol 13:355 CrossRefGoogle Scholar
  73. 73.
    Reith MEA, Berfield JL, Wang LC, Ferrer JV, Javitch JA (2001) J Biol Chem 276:29012 CrossRefGoogle Scholar
  74. 74.
    Chen N, Zhen J, Reith MEA (2004) J Neurochem 89:853 CrossRefGoogle Scholar
  75. 75.
    Ukairo OT, Bondi CD, Newman AH, Kulkarni SS, Kosikowski AP, Pan S, Surratt CK (2005) J Pharmacol Exp Ther 314:575 CrossRefGoogle Scholar
  76. 76.
    Vaughan RA, Sakrikar DS, Parnas ML, Foster JD, Duval RA, Lever JR, Kulkarni SS, Newman AH (2007) J Biol Chem 282:8915 CrossRefGoogle Scholar
  77. 77.
    Zou M, Kopajtic TA, Katz JL, Wirtz S, Justice JJ, Newman AH (2001) J Med Chem 44:4453 CrossRefGoogle Scholar
  78. 78.
    Parnas ML, Gaffaney JD, Zou MF, Lever JR, Newman AH, Vaughan RA (2008) Mol Pharm e-pub Jan 23rd Google Scholar
  79. 79.
    Loland CJ, Norregaard L, Litman T, Gether U (2002) Proc Natl Acad Sci USA 99:1683 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  1. 1.Medications Discovery Research Branch, National Institute on Drug Abuse Intramural ResearchProgramNational Institutes of HealthBaltimoreUSA
  2. 2.Medicinal Chemistry SectionNIDA-IRP, NIHBaltimoreUSA
  3. 3.Psychobiology SectionNIDA-IRP, NIHBaltimoreUSA

Personalised recommendations